Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Vorapaxar for secondary prevention in the elderly with peripheral artery disease: Insights from the TRA 2°P-TIMI 50 trial.

Patel SM, Morrow DA, Kidd SK, Goodrich EL, Scirica BM, Bonaca MP.

Vasc Med. 2019 Apr;24(2):159-161. doi: 10.1177/1358863X19826681. Epub 2019 Mar 14. No abstract available.

PMID:
30868939
2.

Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar: Insights From the TRA 2°P-TIMI 50 Trial.

Bonaca MP, Creager MA, Olin J, Scirica BM, Gilchrist IC Jr, Murphy SA, Goodrich EL, Braunwald E, Morrow DA.

JACC Cardiovasc Interv. 2016 Oct 24;9(20):2157-2164. doi: 10.1016/j.jcin.2016.07.034.

3.

New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 °P-TIMI 50 trial.

Bonaca MP, Scirica BM, Braunwald E, Wiviott SD, Goto S, Nilsen DW, Bonarjee V, Murphy SA, Morrow DA.

J Am Coll Cardiol. 2014 Dec 9;64(22):2318-26. doi: 10.1016/j.jacc.2014.07.997. Epub 2014 Dec 1.

4.

Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2° P-TIMI 50 trial.

Bonaca MP, Scirica BM, Braunwald E, Wiviott SD, O'Donoghue ML, Murphy SA, Morrow DA.

J Am Coll Cardiol. 2014 Dec 9;64(22):2309-17. doi: 10.1016/j.jacc.2014.09.037. Epub 2014 Dec 1.

5.

Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial.

Scirica BM, Bonaca MP, Braunwald E, De Ferrari GM, Isaza D, Lewis BS, Mehrhof F, Merlini PA, Murphy SA, Sabatine MS, Tendera M, Van de Werf F, Wilcox R, Morrow DA; TRA 2°P-TIMI 50 Steering Committee Investigators.

Lancet. 2012 Oct 13;380(9850):1317-24. doi: 10.1016/S0140-6736(12)61269-0. Epub 2012 Aug 26.

PMID:
22932716
6.

Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2°P-TIMI 50 trial.

Kosova EC, Bonaca MP, Dellborg M, He P, Morais J, Oude Ophuis T, Scirica BM, Tendera M, Theroux P, Braunwald E, Morrow DA.

Eur Heart J Acute Cardiovasc Care. 2017 Mar;6(2):164-172. doi: 10.1177/2048872616644910. Epub 2016 Sep 20.

PMID:
27075924
7.

Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50).

Bonaca MP, Gutierrez JA, Creager MA, Scirica BM, Olin J, Murphy SA, Braunwald E, Morrow DA.

Circulation. 2016 Mar 8;133(10):997-1005. doi: 10.1161/CIRCULATIONAHA.115.019355. Epub 2016 Jan 29.

PMID:
26826179
8.

Efficacy and safety of vorapaxar as approved for clinical use in the United States.

Magnani G, Bonaca MP, Braunwald E, Dalby AJ, Fox KA, Murphy SA, Nicolau JC, Oude Ophuis T, Scirica BM, Spinar J, Theroux P, Morrow DA.

J Am Heart Assoc. 2015 Mar 19;4(3):e001505. doi: 10.1161/JAHA.114.001505. Erratum in: J Am Heart Assoc. 2015 Apr;4(4). pii: e000633. doi: 10.1161/JAHA.115.000633.

9.

State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease.

Du M, Chase M, Oguz M, Davies G.

Curr Med Res Opin. 2017 Sep;33(9):1535-1543. doi: 10.1080/03007995.2017.1301902. Epub 2017 Mar 12.

PMID:
28277861
10.

Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2°P-TIMI 50.

Bohula EA, Aylward PE, Bonaca MP, Corbalan RL, Kiss RG, Murphy SA, Scirica BM, White H, Braunwald E, Morrow DA.

Circulation. 2015 Nov 17;132(20):1871-9. doi: 10.1161/CIRCULATIONAHA.114.015042. Epub 2015 Sep 3.

PMID:
26338971
11.

Vorapaxar in the secondary prevention of atherothrombosis.

Tantry US, Liu F, Chen G, Gurbel PA.

Expert Rev Cardiovasc Ther. 2015 Dec;13(12):1293-305. doi: 10.1586/14779072.2015.1109447. Epub 2015 Nov 12. Review.

PMID:
26559689
12.

Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis.

Diehl P, Bode C, Duerschmied D.

Ther Clin Risk Manag. 2015 Aug 3;11:1133-8. doi: 10.2147/TCRM.S55469. eCollection 2015. Review.

13.

Vorapaxar: a review of its use in the long-term secondary prevention of atherothrombotic events.

Frampton JE.

Drugs. 2015 May;75(7):797-808. doi: 10.1007/s40265-015-0387-9. Review.

PMID:
25895464
14.

Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50.

Kidd SK, Bonaca MP, Braunwald E, De Ferrari GM, Lewis BS, Merlini PA, Murphy SA, Scirica BM, White HD, Morrow DA.

J Am Heart Assoc. 2016 Jul 18;5(7). pii: e003237. doi: 10.1161/JAHA.116.003237.

15.

Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER).

Jones WS, Tricoci P, Huang Z, Moliterno DJ, Harrington RA, Sinnaeve PR, Strony J, Van de Werf F, White HD, Held C, Armstrong PW, Aylward PE, Chen E, Patel MR, Mahaffey KW.

Am Heart J. 2014 Oct;168(4):588-96. doi: 10.1016/j.ahj.2014.06.017. Epub 2014 Jul 4.

PMID:
25262270
16.

Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50.

Bonaca MP, Scirica BM, Creager MA, Olin J, Bounameaux H, Dellborg M, Lamp JM, Murphy SA, Braunwald E, Morrow DA.

Circulation. 2013 Apr 9;127(14):1522-9, 1529e1-6. doi: 10.1161/CIRCULATIONAHA.112.000679. Epub 2013 Mar 15.

PMID:
23501976
17.

Vorapaxar expands antiplatelet options.

Duerschmied D, Bode C.

Hamostaseologie. 2012;32(3):221-227. doi: 10.5482/HAMO-12-05-0006. Epub 2017 Dec 28.

PMID:
29589363
18.

Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50).

Berg DD, Bonaca MP, Braunwald E, Corbalan R, Goto S, Kiss RG, Murphy SA, Scirica BM, Spinar J, Morrow DA.

Am J Cardiol. 2016 Apr 1;117(7):1055-8. doi: 10.1016/j.amjcard.2015.12.052. Epub 2016 Jan 14.

PMID:
26876014
19.

Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction.

Kehinde O, Kunle R.

J Pharm Bioallied Sci. 2016 Apr-Jun;8(2):98-105. doi: 10.4103/0975-7406.171690. Review.

20.

Vorapaxar monotherapy for secondary stroke prevention: A call for randomized trial.

Serebruany VL, Kim MH, Hanley DF.

Int J Stroke. 2016 Aug;11(6):614-7. doi: 10.1177/1747493016632253. Epub 2016 Feb 9. Review.

PMID:
26860124

Supplemental Content

Support Center